Clinical effect and safety of S-1 combined with paclitaxel in treatment of advanced gastric cancer
10.7501/j.issn.1674-6376.2017.04.023
- VernacularTitle:替吉奥、顺铂联合紫杉醇对进展期胃癌的疗效和安全性研究
- Author:
Aifeng YANG
- Keywords:
S-1;
cisplatin;
paclitaxel;
advanced gastric cancer;
effect
- From:
Drug Evaluation Research
2017;40(4):549-552
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect and safety of S-1 combined with paclitaxel in treatment of advanced gastric cancer.Methods 80 patients with advanced gastric cancer accepted in our hospital from Sep.2013 to Dec.2015 were selected and randomly divided into 2 groups.Patients in observation group were given S-l,cisplatin and paclitaxel,and patients in control group were given S-1 and paclitaxel.Then the short term and long term clinical effect and adverse reactions of 2 groups were compared.Results The total effective rate of observation group was 52.50％ (21/40),which was obviously higher than 40.00％ (16/40) of control group (P ＜ 0.05).The median progression-free survival,median overall survival and 1 year survival rate of 2 groups had no great differences.The main adverse reaction of 2 groups were bone marrow suppression and gastrointestinal reactions of grade 0～Ⅱ.The grade of nausea and vomiting of observation group was much lighter than control group (P ＜ 0.05).But the other adverse reaction of 2 groups had no differences.Conclusion Using S-l,cisplatin and paclitaxel has good effect in treatment of advanced gastric cancer,which is safety and worthy of clinical applications.
